Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda America to take over URL Pharma
With the completion of the acquisition, URL Pharma will be managed by Takeda Pharmaceuticals USA. Pending the satisfaction of customary closing conditions, the deal is expected to close
With the completion of the acquisition, URL Pharma will be managed by Takeda Pharmaceuticals USA. Pending the satisfaction of customary closing conditions, the deal is expected to close
The non-exclusive distribution agreement is for a one-year period and covers the New York Tri-state area. The initial order is for approximately $70,000 retail value, the company said.
Certification was granted by the Federal Agency for Medicines and Health Products (FAMHP) in Belgium. The Mont-St-Guibert production facilities are used in the manufacture and testing of Cardio3
Under the agreement, the companies will conduct a feasibility study to develop a dry powder inhaler (DPI) dosage form for a RespiVert compound. SkyePharma chief executive officer Peter
The Chozn platform enables faster, simpler selection and scale-up of high-producing clones for the production of recombinant protein drugs. The new platform consists of the cGMP-produced and tested
The test, which uses a proprietary chemistry that eliminates the need for nucleic-acid extraction, is performed on liquid or unformed human stool samples and detects the toxin B
As per the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kourim, Czech Republic. With the agreement, Lonza will be able to seek approval
The new solution provides the block randomization methodology, to assign newly enrolled patients to a treatment group, in addition to the allocation methodology. Balance offers sponsors built-in simulation
Statistically significant progression free survival benefit was achieved in 214-patient randomized controlled Phase II trial. The 404 trial evaluated the efficacy and safety of two doses of TH-302,
FAMPYRA received Health Canada approval for the symptomatic improvement of walking in adult MS patients with walking disability. The approval of FAMPYRA was based on the results of